This suggests that the IL-33/ST2 axis represents an attractive potential immune checkpoint target for AML, and blockade of ST2+ Treg cells either genetically or with engineered neutralizing antibodies showed promising inhibition of AML growth to improve survival in pre-clinical murine and humanized models. This evidence concerns the gene IL33 and acute myeloid leukemia.